| Active Not Recruiting | A Phase 3 Study of BIBP Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsor NCT05091619 | China National Biotec Group Company Limited | Phase 3 |
| Completed | Assessment, Feedback, Incentive, Exchange (AFIX OB) A Customizable Quality Improvement Intervention to Increas NCT04678271 | Yale University | N/A |
| Unknown | A Study to Evaluate the Safety and Efficacy(Immunogenicity) of GC3111 in Healthy Adults NCT04238975 | Green Cross Corporation | Phase 2 |
| Completed | Study of BPZE1 Intranasal Pertussis Vaccine (Administered Via VaxINator(TM)), Prime + Boost, in Healthy Adults NCT03942406 | ILiAD Biotechnologies | Phase 2 |
| Unknown | A Phase 1/2 Clinical Trial of a GamLPV, a Live Intranasal Bordetella Pertussis Vaccine NCT04036526 | Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation | Phase 1 / Phase 2 |
| Completed | Effectiveness of Maternal Immunization With Boostrix at Preventing Pertussis Among Infants <2 Months Old in th NCT03973905 | GlaxoSmithKline | — |
| Completed | Immunising Mums Against Pertussis 3 NCT03578120 | St George's, University of London | — |
| Completed | The Safety of Boostrix Following Routine Immunization of Pregnant Women NCT03463577 | GlaxoSmithKline | — |
| Completed | A Phase I Clinical Study of a GamLPV, a Live Intranasal Bordetella Pertussis Vaccine NCT03137927 | Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation | Phase 1 |
| Unknown | Bordetella Pertussis Colonisation Challenge Study NCT03751514 | University of Southampton | N/A |
| Completed | Observational Study Describing the Immune Profile Induced By Pertussis Vaccines NCT03147898 | Sanofi | — |
| Completed | Viaskin Pertussis Vaccine Trial NCT03035370 | DBV Technologies | Phase 1 |
| Completed | Maternal Tdap Immunization in Guatemala NCT02301702 | Emory University | Phase 2 |
| Unknown | Safety and Immunogenicity Study of Tetanus, Diphtheria and Acellular Pertussis (Tdap) Vaccine NCT02813486 | Green Cross Corporation | Phase 1 / Phase 2 |
| Completed | Study of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed in Healthy Subjec NCT02587520 | Sanofi Pasteur, a Sanofi Company | Phase 1 / Phase 2 |
| Completed | Study of BPZE1 (High Dose) Nasal Live Attenuated B. Pertussis Vaccine NCT02453048 | Institut National de la Santé Et de la Recherche Médicale, France | Phase 1 |
| Unknown | Influence of BCG on TDaP-IPV Vaccination NCT02771782 | Radboud University Medical Center | Phase 4 |
| Completed | Study of DTaP-IPV-Hep B-PRP~T Combined Vaccine in Indian Infants Previously Given a Dose of Hepatitis B Vaccin NCT01948193 | Sanofi Pasteur, a Sanofi Company | Phase 3 |
| Completed | Antibody Persistence at Age 3.5 and 4.5 Years After Primary and Booster DTaP-IPV-Hep B-PRP~T or Infanrix Hexa NCT01983540 | Sanofi Pasteur, a Sanofi Company | Phase 3 |
| Completed | Vouchers to Promote Tdap Vaccination NCT01860378 | Children's Hospital of Philadelphia | EARLY_Phase 1 |
| Completed | Immunogenicity of Adacel® and BOOSTRIX® Vaccines in Adolescents NCT01629589 | Sanofi Pasteur, a Sanofi Company | Phase 4 |
| Completed | Safety and Dose Ranging Study of Acellular Pertussis and Acellular Pertussis -Tetanus-Diphtheria Booster Vacci NCT01529645 | Novartis Vaccines | Phase 1 |
| Completed | Safety and Immunogenicity in Adults of Revaccination With Adacel® Vaccine 10 Years After a Previous Dose NCT01439165 | Sanofi Pasteur, a Sanofi Company | Phase 4 |
| Completed | Study of the Booster Effect of DTaP-IPV-Hep B-PRP~T Combined Vaccine or Infanrix Hexa™ and Prevenar™ in Health NCT01444781 | Sanofi Pasteur, a Sanofi Company | Phase 3 |
| Unknown | Montelukast for Persistent Cough in Young People and Adults NCT01279668 | University of Oxford | Phase 4 |
| Completed | A Study of DTaP-IPV-Hep B-PRP-T Vaccine Given With Prevenar™ and Rotarix™ in Healthy Latin American Infants NCT01177722 | Sanofi Pasteur, a Sanofi Company | Phase 3 |
| Completed | Antibody Persistence in Healthy Children After Primary and Booster DTaP-IPV-Hep B-PRP-T Vaccine or Control Vac NCT01105559 | Sanofi | — |
| Completed | Study of the Environmental Factors Modulating Children Immune Response in Northern Senegal NCT01545115 | Biomedical Research Center EPLS | — |
| Completed | Concomitant Use of Gardasil (V501, Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine) With Combin NCT00337428 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | Concomitant Use of Gardasil (V501) (Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine) With Combi NCT00325130 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | Study of the Safety, Immunogenicity and Lot Comparability of DAPTACEL When Administered With Other Recommended NCT00662870 | Sanofi | Phase 3 |
| Completed | Intravenous Pertussis Immune Globulin in Patients With Severe Childhood Pertussis Infection NCT00004422 | IWK Health Centre | Phase 3 |